Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 513

1.

Preparing pathology for the molecular era.

Bosman FT, Netto GJ.

Virchows Arch. 2017 Jul 17. doi: 10.1007/s00428-017-2198-8. [Epub ahead of print] No abstract available.

PMID:
28714037
2.

The TNM classification of malignant tumours-towards common understanding and reasonable expectations.

O'Sullivan B, Brierley J, Byrd D, Bosman F, Kehoe S, Kossary C, Piñeros M, Van Eycken E, Weir HK, Gospodarowicz M.

Lancet Oncol. 2017 Jul;18(7):849-851. doi: 10.1016/S1470-2045(17)30438-2. No abstract available.

PMID:
28677562
3.

Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.

Altenburg AF, Magnusson SE, Bosman F, Stertman L, de Vries RD, Rimmelzwaan GF.

Clin Exp Immunol. 2017 Jun 30. doi: 10.1111/cei.13004. [Epub ahead of print]

PMID:
28665497
4.

Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, El Zimaity H, Fléjou JF, Hansen TP, Hartmann A, Kakar S, Langner C, Nagtegaal I, Puppa G, Riddell R, Ristimäki A, Sheahan K, Smyrk T, Sugihara K, Terris B, Ueno H, Vieth M, Zlobec I, Quirke P.

Mod Pathol. 2017 May 26. doi: 10.1038/modpathol.2017.46. [Epub ahead of print]

PMID:
28548122
5.

Tumor Heterogeneity: Will It Change What Pathologists Do?

Bosman FT.

Pathobiology. 2017 May 9. doi: 10.1159/000469664. [Epub ahead of print]

PMID:
28482346
6.

Image-based surrogate biomarkers for molecular subtypes of colorectal cancer.

Popovici V, Budinská E, Dušek L, Kozubek M, Bosman F.

Bioinformatics. 2017 Jan 31. doi: 10.1093/bioinformatics/btx027. [Epub ahead of print]

PMID:
28158480
7.

A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients.

van Vlodrop IJH, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, Baldewijns MMLL, Schouten LJ, van den Brandt PA, Jeschke J, Yi JM, Schuebel KE, Ahuja N, Herman JG, Aarts MJ, Bosman FT, Van Criekinge W, van Engeland M.

Clin Cancer Res. 2017 Apr 15;23(8):2006-2018. doi: 10.1158/1078-0432.CCR-16-1236. Epub 2016 Oct 18.

PMID:
27756787
8.

BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.

Barras D, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M.

Clin Cancer Res. 2017 Jan 1;23(1):104-115. doi: 10.1158/1078-0432.CCR-16-0140. Epub 2016 Jun 27.

PMID:
27354468
9.

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data.

Buhl IK, Gerster S, Delorenzi M, Jensen T, Jensen PB, Bosman F, Tejpar S, Roth A, Brunner N, Hansen A, Knudsen S.

PLoS One. 2016 May 12;11(5):e0155123. doi: 10.1371/journal.pone.0155123. eCollection 2016.

10.

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists.

Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciardi H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK; GARFIELD-AF Investigators.

Br J Haematol. 2016 Aug;174(4):610-23. doi: 10.1111/bjh.14084. Epub 2016 Apr 12.

PMID:
27071942
11.

Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.

Yan P, Klingbiel D, Saridaki Z, Ceppa P, Curto M, McKee TA, Roth A, Tejpar S, Delorenzi M, Bosman FT, Fiocca R.

Clin Cancer Res. 2016 Jun 15;22(12):3037-47. doi: 10.1158/1078-0432.CCR-15-0939. Epub 2016 Feb 9.

12.

Quality in pathology: how good is good? An introduction.

Bosman FT, Lehr HA.

Virchows Arch. 2016 Jan;468(1):1-4. doi: 10.1007/s00428-015-1896-3. No abstract available.

PMID:
26754673
13.

DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.

Nygård SB, Vainer B, Nielsen SL, Bosman F, Tejpar S, Roth A, Delorenzi M, Brünner N, Budinska E.

Clin Cancer Res. 2016 Apr 1;22(7):1621-31. doi: 10.1158/1078-0432.CCR-15-0561. Epub 2015 Nov 5.

14.

Communication skills in diagnostic pathology.

Lehr HA, Bosman FT.

Virchows Arch. 2016 Jan;468(1):61-7. doi: 10.1007/s00428-015-1848-y. Epub 2015 Oct 19.

PMID:
26481246
15.

[Molecular pathology of colon cancer].

Bosman FT, Yan P.

Pol J Pathol. 2014 Dec;65(4 Suppl 1):S1-11. Review. Polish. No abstract available.

PMID:
26165028
16.

Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.

Jensen NF, Stenvang J, Beck MK, Hanáková B, Belling KC, Do KN, Viuff B, Nygård SB, Gupta R, Rasmussen MH, Tarpgaard LS, Hansen TP, Budinská E, Pfeiffer P, Bosman F, Tejpar S, Roth A, Delorenzi M, Andersen CL, Rømer MU, Brünner N, Moreira JM.

Mol Oncol. 2015 Jun;9(6):1169-85. doi: 10.1016/j.molonc.2015.02.008. Epub 2015 Feb 24.

17.

Response.

Delorenzi M, Tejpar S, Roth AD, Bosman FT; all authors.

J Natl Cancer Inst. 2015 Mar 10;107(5). pii: djv056. doi: 10.1093/jnci/djv056. No abstract available.

PMID:
25758032
18.

Molecular pathology of colorectal cancer.

Bosman F, Yan P.

Pol J Pathol. 2014 Dec;65(4):257-66. Review.

19.

The good, the bad, and the ugly.

Bosman FT.

Virchows Arch. 2015 Jan;466(1):1. doi: 10.1007/s00428-014-1707-2. No abstract available.

PMID:
25527271
20.

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S.

Ann Oncol. 2015 Jan;26(1):126-32. doi: 10.1093/annonc/mdu499. Epub 2014 Oct 30.

PMID:
25361982

Supplemental Content

Loading ...
Support Center